HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

AuthorsVienna Ludovini, Stefania Gori, Lorenza Pistola, Maria Agnese Della Fazia, Danilo Piobbico, Giuseppe Servillo, Antonella Flacco, Cristina Scuderi, Lucio Crinò
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 3 Issue 4 Pg. 452-3 (Apr 2008) ISSN: 1556-1380 [Electronic] United States
PMID18379371 (Publication Type: Case Reports, Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Deoxycytidine
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • Cisplatin
  • Gemcitabine
Topics
  • Adenocarcinoma, Bronchiolo-Alveolar (drug therapy, genetics, secondary)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Cisplatin (administration & dosage)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • ErbB Receptors (antagonists & inhibitors, genetics)
  • Humans
  • Immunoenzyme Techniques
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms (drug therapy, genetics, pathology)
  • Male
  • Middle Aged
  • Mutation (genetics)
  • Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism)
  • Remission Induction
  • Tomography Scanners, X-Ray Computed
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: